Raymond Chien
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Raymond Chien has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Jin Xu
Rutgers New Jersey Medical School
3 shared publications- Ying-Xian Pan
Department of Anesthesiology, Rutgers New Jersey Medical School, Newark, NJ 07103, USA
3 shared publications Arlene Martínez-Rivera
Temple University
2 shared publications- Ayma F. Malik
Department of Anesthesiology, New Jersey Medical School, Newark, NJ 07103, USA
2 shared publications Bing Wang
Rutgers New Jersey Medical School
2 shared publications- Eric Lieberman Greer
Washington University School of Medicine in St. Louis
2 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Springer Nature in Research Square
Reversible m6Am methylation of snRNA by FTO controls morphine reward and tolerance without altering analgesia
Mu opioids, such as morphine, are effective analgesics, but they produce reward and tolerance that lead to opioid use disorder. A major goal is to achieve analgesia without these harmful effects. Here we show that morphine reward and tolerance are controlled by a reversible RNA modification in small nuclear RNA (snRNA) that is removed by the RNA demethylase FTO. Genetic depletion and pharmacologic inhibition of FTO each reduced morphine reward, measured by conditioned-place preference, and reduced tolerance to morphine and fentanyl, without altering analgesia. Depleting Fto in the nucleus accumbens shell reduced reward but not tolerance, while depleting Fto in the dorsal root ganglion reduced tolerance but not reward, suggesting region-specific effects of FTO. Although FTO is known to erase m 6 A on mRNA, we found no effect of FTO depletion on m 6 A sites, but a marked increase in m 6 Am levels in snRNA. The effects of FTO depletion were suppressed in mice that cannot make m 6 Am, supporting the importance of elevated m 6 Am in suppressing morphine reward and tolerance. Consistent with altered snRNA function, FTO depletion reshapes gene expression linked to morphine signaling. FTO inhibitors may therefore provide useful adjuvants for mu opioids in pain management and treatment of opioid use disorder.
- 2 November 2026
- Published by Springer Nature in Research Square
Open AccessReversible m6Am methylation of snRNA by FTO controls morphine reward and tolerance without altering analgesia
Mu opioids, such as morphine, are effective analgesics, but they produce reward and tolerance that lead to opioid use disorder. A major goal is to achieve analgesia without these harmful effects. Here we show that morphine reward and tolerance are controlled by a reversible RNA modification in small nuclear RNA (snRNA) that is removed by the RNA demethylase FTO. Genetic depletion and pharmacologic inhibition of FTO each reduced morphine reward, measured by conditioned-place preference, and reduced tolerance to morphine and fentanyl, without altering analgesia. Depleting Fto in the nucleus accumbens shell reduced reward but not tolerance, while depleting Fto in the dorsal root ganglion reduced tolerance but not reward, suggesting region-specific effects of FTO. Although FTO is known to erase m 6 A on mRNA, we found no effect of FTO depletion on m 6 A sites, but a marked increase in m 6 Am levels in snRNA. The effects of FTO depletion were suppressed in mice that cannot make m 6 Am, supporting the importance of elevated m 6 Am in suppressing morphine reward and tolerance. Consistent with altered snRNA function, FTO depletion reshapes gene expression linked to morphine signaling. FTO inhibitors may therefore provide useful adjuvants for mu opioids in pain management and treatment of opioid use disorder.
- Open Access
Reversible m 6 Am methylation of snRNA by FTO controls morphine reward and tolerance without altering analgesia
SUMMARY: Mu opioids, such as morphine, are effective analgesics, but their reward and tolerance drive opioid use disorder. A major goal is to achieve analgesia without these harmful effects. Here we show that morphine reward and tolerance require the RNA demethylase FTO. Genetic depletion and pharmacologic inhibition of FTO each reduced morphine reward, measured by conditioned-place preference, and reduced antinociceptive tolerance to morphine and fentanyl, without altering analgesia. Although FTO is known to erase m 6 A on mRNA, we found no effect of FTO depletion on m 6 A sites, but markedly increased levels of m 6 Am on snRNA. The effects of FTO depletion were suppressed in mice that cannot make m 6 Am, supporting the role of m 6 Am in morphine reward and tolerance. We show that FTO depletion regulates a gene expression network linked to morphine signaling. FTO inhibitors may therefore provide useful adjuvants to mu opioids in pain management and treatment of opioid use disorder.
Open AccessReversible m 6 Am methylation of snRNA by FTO controls morphine reward and tolerance without altering analgesia
SUMMARY: Mu opioids, such as morphine, are effective analgesics, but their reward and tolerance drive opioid use disorder. A major goal is to achieve analgesia without these harmful effects. Here we show that morphine reward and tolerance require the RNA demethylase FTO. Genetic depletion and pharmacologic inhibition of FTO each reduced morphine reward, measured by conditioned-place preference, and reduced antinociceptive tolerance to morphine and fentanyl, without altering analgesia. Although FTO is known to erase m 6 A on mRNA, we found no effect of FTO depletion on m 6 A sites, but markedly increased levels of m 6 Am on snRNA. The effects of FTO depletion were suppressed in mice that cannot make m 6 Am, supporting the role of m 6 Am in morphine reward and tolerance. We show that FTO depletion regulates a gene expression network linked to morphine signaling. FTO inhibitors may therefore provide useful adjuvants to mu opioids in pain management and treatment of opioid use disorder.
- Open Access
- 17 February 2026
- Published by Elsevier in Molecular Pharmacology
- Vol. 108 (4) , 100112
Differential impacts of exon 1–associated and exon 11–associated variants of the rat mu opioid receptor gene, Oprm1, on buprenorphine- and morphine-induced analgesia and respiratory depression in male rats
- 17 February 2026
- Published by Elsevier in Molecular Pharmacology
- Vol. 108 (4) , 100112
Open AccessDifferential impacts of exon 1–associated and exon 11–associated variants of the rat mu opioid receptor gene, Oprm1, on buprenorphine- and morphine-induced analgesia and respiratory depression in male rats